Brief: 4D Molecular Therapeutics Expects Primary Endpoint 52-Week Topline Data For Both 4FRONT-1 And 4FRONT-2 In H2 2027
10/01/2025 13:28
Jan 10 (Reuters) - 4D Molecular Therapeutics Inc
FDMT.O :
* 4D MOLECULAR THERAPEUTICS INC: PRIMARY ENDPOINT 52-WEEK
TOPLINE
DATA FOR BOTH 4FRONT-1 AND 4FRONT-2 EXPECTED IN H2 2027
* 4D MOLECULAR THERAPEUTICS INC: CASH RUNWAY EXTENDED UNDER
UPDATED OPERATING PLAN EXPECTED TO FUND OPERATIONS INTO 2028
Source text: urn:newsml:reuters.com:*:nGNX41gQNr
Further company coverage: FDMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 4D Molecular Therapeutics
See all news4D Molecular Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
4D Molecular Therapeutics Q2 net loss widens
Brief: 4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview
Brief: 4d Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings